سعر ابيزولون-ديبوت 40مجم/مل 1 مل فيال 2025

Methylprednisolone acetate 40 mg/ml aqueous suspension for injection (IM, intra-articular, soft-tissue or intralesional), 1 ml vial (EIPICO Epizolone-Depot).

• Intramuscular (systemic) use: rheumatoid arthritis, systemic lupus erythematosus, severe erythema multiforme (Stevens-Johnson syndrome), bronchial asthma, drug hypersensitivity reactions, angioneurotic oedema, ulcerative colitis, Crohn's disease, fulminating or disseminated tuberculosis and TB meningitis (with antituberculous therapy), aspiration of gastric contents.Ethiopian Food and Drug Authority (EFDA)
• Intra-articular and soft-tissue use: rheumatoid arthritis, osteoarthritis with an inflammatory component, non-infective synovitis, epicondylitis, tenosynovitis, plantar fasciitis, bursitis.Ethiopian Food and Drug Authority (EFDA)
• Intralesional use: keloids, localized lichen planus and lichen simplex, granuloma annulare, discoid lupus erythematosus, alopecia areata.Ethiopian Food and Drug Authority (EFDA)

• Corticosteroid class effects (frequency not known): increased susceptibility to infection, Cushingoid state, adrenal suppression and withdrawal symptoms on rapid reduction, glucose intolerance, fluid and sodium retention, hypokalaemia, mood and psychotic disturbances, cataract, glaucoma, hypertension, thrombotic events.International label, same product · Ethiopian Food and Drug Authority (EFDA)

• Hypersensitivity to the active substance or excipients; systemic infection without specific anti-infective therapy; intrathecal or intravenous use; live or live-attenuated vaccines with immunosuppressive doses; systemic fungal infection (except intra-articular use for localized joint conditions); IM use in idiopathic thrombocytopenic purpura.International label, same product · Ethiopian Food and Drug Authority (EFDA)

• Severe medical events have been reported with intrathecal/epidural administration; take measures to avoid intravascular injection. Vials are single-dose only; multidose use may cause contamination.International label, same product · Ethiopian Food and Drug Authority (EFDA)
• Use the lowest effective dose for the minimum period; frequent patient review is required to titrate the dose against disease activity.International label, same product · Ethiopian Food and Drug Authority (EFDA)

• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, erythromycin, troleandomycin, grapefruit juice)Decrease methylprednisolone clearance and may increase its effects and adverse effects; dose titration may be needed.Ethiopian Food and Drug Authority (EFDA)
• CYP3A4 inducers (e.g., rifampicin, rifabutin, carbamazepine, phenobarbitone, phenytoin, primidone)Enhance corticosteroid metabolism and may reduce its effect; a dose increase may be required.Ethiopian Food and Drug Authority (EFDA)
• CiclosporinConvulsions reported with concurrent use; mutual inhibition of metabolism.Ethiopian Food and Drug Authority (EFDA)

• Methylprednisolone crosses the placenta; low birth weight (dose related) and intra-uterine growth retardation with prolonged or repeated use have been reported; neonates exposed to substantial doses should be observed for adrenal insufficiency. Use only after careful benefit-risk assessment.International label, same product · Ethiopian Food and Drug Authority (EFDA)
• Corticosteroids are excreted in small amounts in breast milk; methylprednisolone doses up to 40 mg daily are unlikely to cause systemic effects in the infant. Use during breastfeeding only after benefit-risk assessment.International label, same product · Ethiopian Food and Drug Authority (EFDA)

• Methylprednisolone acetate: Synthetic glucocorticoid with anti-inflammatory and immunosuppressive activity; the acetate ester gives a depot effect (EIPICO SmPC).